Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Year: 2023
Type: article
Study design: Observational Study
Source: Anti-Cancer Drugs
Authors: Muhamad Alhaj Moustafa, Ricardo Parrondo, Mays F. Abdulazeez, Vivek Roy, Taimur Sher, Victoria R. Alegria, Rahma M. Warsame, Rafael Fonseca, Ahsan Rasheed, Wilson I. Gonsalves, Taxiarchis Kourelis, Prashant Kapoor, Francis K. Buadi, David Dingli, Suzanne R. Hayman, Craig B. Reeder, Asher A. Chanan-Khan, Sikander Ailawadhi
Institutions: Mayo Clinic, Mayo Clinic in Florida, Mayo Clinic Hospital
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4366082830